CooperVision Research at ARVO 2026 Advances Understanding of Myopia Control, Orthokeratology, and Contact Lens Comfort
ROCHESTER, N.Y., June 8, 2026—A new analysis of an ongoing randomized controlled trial of MiSight® 1 day* soft contact lenses suggests that the product's myopia control efficacy may be conservatively reported. The finding points to attrition bias—the tendency of faster progressing children in the untreated group to withdraw from a study to seek alternative care—as a key factor influencing how trial results are interpreted. The findings were presented at the ARVO 2026 Annual Meeting, held May 3–7 in Denver, Colorado.
The research, Impact of Withdrawn Subjects on Bias in a Myopia Control Trial1, examined data from a multi-site, double-masked, randomized controlled trial enrolling 191 myopic children (ages 7–11) in China, randomized to MiSight® 1 day or a standard single-vision contact lens. Eye growth was measured at baseline, six, and 12 months. Children assigned to the single vision group who dropped out before the study's end showed faster eye growth in the first six months (0.34 mm) than those who stayed (0.20 mm), suggesting that the children with the greatest need for myopia control were most likely to leave the study. No such pattern emerged among MiSight® 1 day wearers. When the investigators accounted for these dropouts, the findings suggested the treatment effect at 12 months may have been understated. The authors concluded that failing to account for this dropout pattern can lead standard trial analysis to underestimate MiSight® 1 day’s true treatment effect.
“Advancing vision care requires ongoing scrutiny of both our innovations and the data that support them,” said Elizabeth Lumb, Director, Global Professional Affairs, Myopia Management, CooperVision. “Our research-led approach extends to understanding how study dynamics, such as higher dropout among faster-progressing untreated children may influence efficacy outcomes. As awareness of myopia control continues to grow, recruiting control groups is also likely to become more challenging, further shaping how future evidence is generated and interpreted. By continually refining our approach, we aim to strengthen the evidence base and improve standards of care for children with myopia.”
CooperVision scientists and research partners also shared additional work with ARVO attendees throughout the week. Frequency of Effectiveness of First Choice CRT Contact Lenses (CL) Parameters in Patients Undergoing Temporary Myopia Therapy (Ortho-K) and Its Analysis2, examined orthokeratology fitting outcomes. The study found that the Paragon CRT® 100 Initial Lens Selector achieved target visual acuity in approximately 80% of eyes on the first lens selection. The findings support the reliability of the CRT lens-selection process for practitioners offering temporary myopia therapy to patients.
Continuing its commitment to advancing contact lens comfort research, CooperVision also presented Impact of No-Lens Washout on Ocular Discomfort in Long-Term and Recent Contact Lens Wearers3. Researchers investigated how a structured no-lens-wear washout period affects contact lens discomfort (CLD) symptoms upon rechallenge. Symptoms declined during the rechallenge phase in both long-standing and recently developed CLD groups, with the greatest improvement seen in patients with established CLD. The results suggest that a lens-free period may partially reverse altered sensory function associated with ocular irritation, though individual responses varied, pointing to complex adaptive mechanisms in ocular surface recovery.
For more information about ARVO 2026 and read all abstracts, visit https://www.arvo.org/annual-meeting/.
# # #
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1.585.434.2148
SA18739/APP166552
* Indications for use: MiSight® 1 day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to - 4.00 D (spherical equivalent) with 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
1Srinivasan V. et al. Impact of Withdrawn Subjects on Bias in a Myopia Control Trial. ARVO 2026 poster presentation.
2Schaefer T. et al. Frequency of Effectiveness of First Choice CRT Contact Lenses (CL) Parameters in Patients Undergoing Temporary Myopia Therapy (Ortho-K) and Its Analysis. ARVO 2026 poster presentation.
3Situ P. et al. Impact of No-Lens Washout on Ocular Discomfort in Long-Term and Recent Contact Lens Wearers. ARVO 2026 poster presentation.